MedTrace Logo

Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

NCT06014320 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-08-28

No results posted yet for this study

Summary

The goal of this observational study is to learn about the changes in coagulation factor VIII and IX levels in patients undergoing liver transplantation to help guide future management of coagulation factor replacement in patients with hemophilia and liver disease. The question we aim to answer is: should the recommendations for factor replacement in patients with hereditary bleeding disorders be altered in the setting of end stage liver cirrhosis?

Participants will be asked to provide two blood samples, one at the beginning of their liver transplant, and one after their liver transplant.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Alexandra Ruan, MD · Stanford University

  • Martin Angst, MD · Stanford University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-04-01
Completion
2024-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014320 on ClinicalTrials.gov